Bn Immunotherapeutics, Inc.

Bavarian Nordic A/s

Stefanie Mandl

Alain Delcayre

Alex Franzusoff

Reiner Laus

Ryan Blair Rountree

Fatema Legrand

The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B-and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.

Use of MVA to treat prostate cancer

The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.

Methods for treating cancer with a recombinant MVA expressing HER-2

The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.

Growing community of inventors

San Francisco, CA, United States of America

Stefanie Mandl